Effects of Interpectoral-Pectoserratus Plane Block After Breast Cancer Surgery
The Effects of Intraoperative and Preoperative Interpectoral -Pectoserratus Plan Block on Postoperative Pain, Amount of Analgesic Use, and Shoulder Joint Range of Motion in Patients Who Had Breast Cancer Surgery
1 other identifier
observational
60
1 country
1
Brief Summary
The aim of this study: It was aimed to observe the effects of intraoperative and preoperative PECS II block on postoperative pain, amount of analgesic use and shoulder joint range of motion in patients who underwent breast cancer surgery. This research was planned as an observational study. For this purpose, patients who underwent breast cancer surgery in İzmir Bakırçay University Çiğli Training and Research Hospital General Surgery Clinic will be included in the study at the 1st hour after the operation. Patients who underwent preoperative Interpectoral - Pectoserratus Plan Block in the operation will be included in Group 1, patients who have been applied Interpectoral - Pectoserratus Plan Block between the muscle planes by the intraoperative surgeon will be included in Group 2, and patients who have not applied any block will be included in Group 3. Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia, adverse events (pneumothorax, nausea, vomiting, itching, hematoma, allergic reactions) and quality of life, shoulder joint range of motion, hand grip strength (also on day 1) and disability level will be measured on postoperative day 10. H0- Preoperative interpectoral - pectoserratus plane block affects the level of postoperative pain. H1- Preoperativeinterpectoral - pectoserratus plane block does not affect the level of postoperative pain. H2- Intraoperative interpectoral - pectoserratus plane block affects postoperative pain level H3- Intraoperative interpectoral - pectoserratus plane blockk does not affect the level of postoperative pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 2, 2022
CompletedFirst Posted
Study publicly available on registry
October 5, 2022
CompletedStudy Start
First participant enrolled
October 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 6, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 6, 2023
CompletedOctober 5, 2022
October 1, 2022
3 months
October 2, 2022
October 2, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Postoperative opioid consumption
Tramadol consumption in the first 24 hours after surgery
24 hours
Secondary Outcomes (6)
NRS scores
1., 2., 6., 12., 24. hour
Quality of Recovery
24th hours
The disability levels of the patients due to shoulder dysfunction.
10th day
Hand grip muscle strength.
24th hour, 10th day
Quality of Life (Short Form 36)
24th hour, 10th day
- +1 more secondary outcomes
Study Arms (3)
Preoperative Interpectoral - Pectoserratus Plane Block
The block will be done by the Anesthesiologist.
Intraoperative Interpectoral - Pectoserratus Plane Block
The block will be made by the surgeon.
Non Block
will not be blocked.
Interventions
Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
Eligibility Criteria
Sixty patients aged \>18 years old who has breast cancer surgery with intraoperative or preoperative interpectoral - pectoserratus plane block o non block will be included in the study. Patients will be randomly divided into three groups including 20 patients each, postoperative 1st hour.
You may qualify if:
- Having had a unilateral breast cancer operation
- Signing the voluntary consent form
You may not qualify if:
- BMI \>35kg/m2 and \<20kg/m2
- Having a rheumatological disease (rheumatoid arthritis, etc.),
- Having neuromuscular disease
- Having a disease that will add shoulder joint movement (arthritis, prosthesis, fracture sequela, etc.)
- Having neuropathy, alcoholism, psychiatric disorder
- Chronic opioid use
- being pregnant
- Patient's refusal to use patient-controlled analgesia
- History of uncontrolled hypertension, diabetes, heart failure, liver failure, kidney failure and/or cerebrovascular disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Izmir Bakircay University Cigli Training and Research Hospital
Izmir, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ömer Faruk Altaş, 1
İzmir Bakircay University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Specialist
Study Record Dates
First Submitted
October 2, 2022
First Posted
October 5, 2022
Study Start
October 6, 2022
Primary Completion
January 6, 2023
Study Completion
April 6, 2023
Last Updated
October 5, 2022
Record last verified: 2022-10
Data Sharing
- IPD Sharing
- Will not share